MNKD Mannkind Corp

Price (delayed)

$4.07

Market cap

$1.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.34

Enterprise value

$1.39B

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its ...

Highlights
Mannkind's gross profit has soared by 81% from the previous quarter and by 16% YoY
The revenue has grown by 32% YoY and by 31% from the previous quarter
Mannkind's gross margin has increased by 38% QoQ but it has decreased by 13% YoY
Mannkind's EPS has increased by 11% from the previous quarter but it has decreased by 6% YoY
Mannkind's quick ratio has decreased by 35% YoY and by 12% QoQ
The equity has declined by 20% year-on-year and by 5% since the previous quarter

Key stats

What are the main financial stats of MNKD
Market
Shares outstanding
263.92M
Market cap
$1.07B
Enterprise value
$1.39B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
10.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.91
Earnings
Revenue
$99.77M
EBIT
-$62.63M
EBITDA
-$53.52M
Free cash flow
-$88.27M
Per share
EPS
-$0.34
Free cash flow per share
-$0.34
Book value per share
-$0.95
Revenue per share
$0.39
TBVPS
$1.13
Balance sheet
Total assets
$295.28M
Total liabilities
$545.82M
Debt
$382.91M
Equity
-$250.54M
Working capital
$167.6M
Liquidity
Debt to equity
-1.53
Current ratio
3.49
Quick ratio
2.79
Net debt/EBITDA
-5.85
Margins
EBITDA margin
-53.6%
Gross margin
42.4%
Net margin
-87.6%
Operating margin
-69.1%
Efficiency
Return on assets
-29.5%
Return on equity
N/A
Return on invested capital
-11.2%
Return on capital employed
-27.5%
Return on sales
-62.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNKD stock price

How has the Mannkind stock price performed over time
Intraday
-2.16%
1 week
-8.95%
1 month
-27.71%
1 year
12.74%
YTD
-22.77%
QTD
-22.77%

Financial performance

How have Mannkind's revenue and profit performed over time
Revenue
$99.77M
Gross profit
$42.27M
Operating income
-$68.92M
Net income
-$87.4M
Gross margin
42.4%
Net margin
-87.6%
Mannkind's gross profit has soared by 81% from the previous quarter and by 16% YoY
MNKD's operating margin is up by 38% since the previous quarter and by 2.7% year-on-year
Mannkind's gross margin has increased by 38% QoQ but it has decreased by 13% YoY
The revenue has grown by 32% YoY and by 31% from the previous quarter

Growth

What is Mannkind's growth rate over time

Valuation

What is Mannkind stock price valuation
P/E
N/A
P/B
N/A
P/S
10.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.91
Mannkind's EPS has increased by 11% from the previous quarter but it has decreased by 6% YoY
The equity has declined by 20% year-on-year and by 5% since the previous quarter
The revenue has grown by 32% YoY and by 31% from the previous quarter
The P/S is 19% lower than the last 4 quarters average of 13.0 and 7% lower than the 5-year quarterly average of 11.3

Efficiency

How efficient is Mannkind business performance
Mannkind's ROS has increased by 35% from the previous quarter and by 26% YoY
The company's return on invested capital rose by 26% YoY and by 15% QoQ
The ROA is up by 9% QoQ but it is down by 3.1% YoY

Dividends

What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNKD.

Financial health

How did Mannkind financials performed over time
The company's total assets is 46% lower than its total liabilities
Mannkind's quick ratio has decreased by 35% YoY and by 12% QoQ
The company's current ratio fell by 23% YoY and by 4.6% QoQ
The equity has declined by 20% year-on-year and by 5% since the previous quarter
The debt to equity is up by 16% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.